37. Generalised pustular psoriasis Clinical trials / Disease details


Clinical trials : 74 Drugs : 53 - (DrugBank : 20) / Drug target genes : 20 - Drug target pathways : 101

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04183881
(ClinicalTrials.gov)
July 4, 201629/11/2019A Phase 4 Clinical Study of BrodalumabAn Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic ErythrodermaPsoriasis Vulgaris;Psoriatic Arthritis;Pustular; Psoriasis, Palmaris Et Plantaris;Psoriatic ErythrodermaDrug: Brodalumab 210mg SCKyowa Kirin Co., Ltd.NULLCompleted18 YearsN/AAll138Phase 4Japan
2JPRN-JapicCTI-142430
01/2/2014A Phase 3 Clinical Study of KHK4827An Extension Study of KHK4827 Subjects with Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma PsoriasisIntervention name : KHK4827
INN of the intervention : brodalumab
Dosage And administration of the intervention : Subcutaneous administration
Control intervention name : null
Kyowa Hakko Kirin Co., Ltd.NULL18BOTH165Phase 3NULL
3JPRN-JapicCTI-132057
01/2/2013An open-label, non-controlled study of KHK4827 in subjects with psoriasisA Long-Term Study of KHK4827 in Subjects with Pustular Psoriasis (Generalized) and Psoriatic Erythroderma PsoriasisIntervention name : KHK4827
INN of the intervention : brodalumab
Dosage And administration of the intervention : Subcutaneous administration
Control intervention name : null
Kyowa Hakko Kirin Co., Ltd.NULL18BOTHPhase 3NULL